Nicholas Hornstein, Assistant Professor at Northwell Health, shared a post on LinkedIn:
“Drug development is supposed to be linear.
Build the drug – use the drug – resistance shows up – then figure out what to do next.
And not what Revolution Medicines is doing.
At AACR26, they disclosed RM-055, which honestly, is a unique concept.
Before DaraxONRASib is even fully in the world, they’re building around resistance.
How it works:
- Most mutant RAS proteins are relatively resistant to GAP-mediated hydrolysis
- That helps keep RAS in the active state
- They’ve found a way to enhance that hydrolysis with RM-055
RM-055 can:
- restore hydrolysis in mutant RAS
- flatten daraxonrasib-resistant models
- generate activity even in RAS-amplified settings
That’s a very smart way to think about this space.
Not just ‘here’s our inhibitor.’
More like: we already know resistance to our drug is coming, so let’s start building now.
That’s how we cure cancer, not more me-toos (if I hear about another new PD1 program, I’m going to cry).”
Other articles featuring Nicholas Hornstein on OncoDaily.
